The Triterpenoid CDDO-Me Inhibits Bleomycin-Induced Lung Inflammation and Fibrosis

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Kulkarni, Ajit A ^a,b   Thatcher, Thomas H ^a,b   Hsiao, Hsi Min ^a   Olsen, Keith C ^a,b   Kottmann, Robert Matthew ^a,b   Morrissette, Jason ^b   Wright, Terry W ^a   Phipps, Richard P ^a,b   Sime, Patricia J ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BARDOXOLONE METHYL; BLEOMYCIN; COLLAGEN; FIBRONECTIN; INTERLEUKIN 6; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPIRATION; AUTOIMMUNE DISEASE; BREATHING RATE; COLLAGEN METABOLISM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HISTOPATHOLOGY; LUNG ALVEOLUS MACROPHAGE; LUNG COMPLIANCE; LUNG FIBROSIS; LUNG FUNCTION; LUNG LAVAGE; LUNG PARENCHYMA; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PNEUMONIA; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; TREATMENT DURATION;

ACTINS; ADMINISTRATION, INHALATION; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; COLLAGEN; FIBRONECTINS; GENE EXPRESSION; HUMANS; MACROPHAGES, ALVEOLAR; MALE; MICE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; OLEANOLIC ACID; PNEUMONIA; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; TRANSFORMING GROWTH FACTOR BETA;

MUS;

EID: 84878619158     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063798     Document Type: Article

References (47)

1. Kottmann RM, Hogan CM, Phipps RP, Sime PJ, (2009) Determinants of initiation and progression of idiopathic pulmonary fibrosis. Respirology 14: 917-933.
2. Nathan SD, Noble PW, Tuder RM, (2007) Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med 175: 875-880.
3. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P, (2004) Interstitial lung disease induced by drugs and radiation. Respiration 71: 301-326.
4. Limper AH, (2004) Chemotherapy-induced lung disease. Clin Chest Med 25: 53-64.
5. Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA, (2006) Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 17: 372-379.
6. Ding Q, Luckhardt T, Hecker L, Zhou Y, Liu G, et al. (2011) New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis. Drugs 71: 981-1001.
7. Liby KT, Sporn MB, (2012) Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev 64: 972-1003.
8. Auletta JJ, Alabran JL, Kim BG, Meyer CJ, Letterio JJ, (2010) The synthetic triterpenoid, CDDO-Me, modulates the proinflammatory response to in vivo lipopolysaccharide challenge. J Interferon Cytokine Res 30: 497-508.
9. Ferguson HE, Kulkarni A, Lehmann GM, Garcia-Bates TM, Thatcher TH, et al. (2009) Electrophilic peroxisome proliferator-activated receptor-gamma ligands have potent antifibrotic effects in human lung fibroblasts. Am J Respir Cell Mol Biol 41: 722-730.
10. Kulkarni AA, Thatcher TH, Olsen KC, Maggirwar SB, Phipps RP, et al. (2011) PPAR-gamma ligands repress TGFbeta-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis. PLoS One 6: e15909.
11. Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray DM, et al. (2005) PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 288: L1146-1153.
12. Thatcher TH, Benson RP, Phipps RP, Sime PJ, (2008) High-dose but not low-dose mainstream cigarette smoke suppresses allergic airway inflammation by inhibiting T cell function. Am J Physiol Lung Cell Mol Physiol 295: L412-421.
13. Lakatos HF, Burgess HA, Thatcher TH, Redonnet MR, Hernady E, et al. (2006) Oropharyngeal aspiration of a silica suspension produces a superior model of silicosis in the mouse when compared to intratracheal instillation. Exp Lung Res 32: 181-199.
14. Olsen KC, Sapinoro RE, Kottmann RM, Kulkarni AA, Iismaa SE, et al. (2011) Transglutaminase 2 and its role in pulmonary fibrosis. Am J Respir Crit Care Med 184: 699-707.
15. Wright TW, Gigliotti F, Finkelstein JN, McBride JT, An CL, et al. (1999) Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 104: 1307-1317.
16. Bhagwat SP, Wright TW, Gigliotti F, (2010) Anti-CD3 antibody decreases inflammation and improves outcome in a murine model of Pneumocystis pneumonia. J Immunol 184: 497-502.
17. Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, et al. (2011) New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod 74: 537-545.
18. Deeb D, Gao X, Dulchavsky SA, Gautam SC, (2008) CDDO-Me inhibits proliferation, induces apoptosis, down-regulates Akt, mTOR, NF-kappaB and NF-kappaB-regulated antiapoptotic and proangiogenic proteins in TRAMP prostate cancer cells. J Exp Ther Oncol 7: 31-39.
19. Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, et al. (2007) The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res 67: 2414-2419.
20. Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, et al. (2002) Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 99: 326-335.
21. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M, (2008) The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 40: 362-382.
22. Saito F, Tasaka S, Inoue K, Miyamoto K, Nakano Y, et al. (2008) Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am J Respir Cell Mol Biol 38: 566-571.
23. Kawashima M, yatsunami J, Fukuno Y, Nagata M, Tominaga M, et al. (2002) Inhibitory effects of 14-membered ring macrolide antibiotics on bleomycin-induced acute lung injury. Lung 180: 73-89.
24. Phan SH, Kunkel SL, (1992) Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp Lung Res 18: 29-43.
25. Vanoirbeek JA, Rinaldi M, De Vooght V, Haenen S, Bobic S, et al. (2010) Noninvasive and invasive pulmonary function in mouse models of obstructive and restrictive respiratory diseases. Am J Respir Cell Mol Biol 42: 96-104.
26. Heathcote KL, Cockcroft DW, Fladeland DA, Fenton ME, (2011) Normal expiratory flow rate and lung volumes in patients with combined emphysema and interstitial lung disease: a case series and literature review. Can Respir J 18: e73-76.
27. Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, et al. (2011) Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 140: 221-229.
28. Jules-Elysee K, White DA, (1990) Bleomycin-induced pulmonary toxicity. Clin Chest Med 11: 1-20.
29. Kreisman H, Wolkove N, (1992) Pulmonary toxicity of antineoplastic therapy. Semin Oncol 19: 508-520.
30. Suh N, Wang Y, Honda T, Gribble GW, Dmitrovsky E, et al. (1999) A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res 59: 336-341.
31. Place AE, Suh N, Williams CR, Risingsong R, Honda T, et al. (2003) The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res 9: 2798-2806.
32. Honda T, Padegimas EM, David E, Sundararajan C, Liby KT, et al. (2010) 2-Cyano-3,10-dioxooleana-1,9(11)-dien-28-oic acid anhydride. A novel and highly potent anti-inflammatory and cytoprotective agent. Bioorg Med Chem Lett 20: 2275-2278.
33. Hogan CM, Thatcher TH, Sapinoro RE, Gurell MN, Ferguson HE, et al. (2011) Electrophilic PPARgamma Ligands Attenuate IL-1beta and Silica-Induced Inflammatory Mediator Production in Human Lung Fibroblasts via a PPARgamma-Independent Mechanism. PPAR Res 2011: 318134.
34. Thimmulappa RK, Scollick C, Traore K, Yates M, Trush MA, et al. (2006) Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide. Biochem Biophys Res Commun 351: 883-889.
35. Reddy NM, Suryanaraya V, Yates MS, Kleeberger SR, Hassoun PM, et al. (2009) The triterpenoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice. Am J Respir Crit Care Med 180: 867-874.
36. Sogno I, Vannini N, Lorusso G, Cammarota R, Noonan DM, et al. (2009) Anti-angiogenic activity of a novel class of chemopreventive compounds: oleanic acid terpenoids. Recent Results Cancer Res 181: 209-212.
37. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, et al. (2011) Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365: 327-336.
38. Gauldie J, Bonniaud P, Sime P, Ask K, Kolb M, (2007) TGF-beta, Smad3 and the process of progressive fibrosis. Biochem Soc Trans 35: 661-664.
39. Wynn TA, (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199-210.
40. Mi S, Li Z, Yang HZ, Liu H, Wang JP, et al. (2011) Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and-independent mechanisms. J Immunol 187: 3003-3014.
41. Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, et al. (2010) Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 207: 535-552.
42. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J, (2001) Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 107: 1529-1536.
43. Wang Y, Porter WW, Suh N, Honda T, Gribble GW, et al. (2000) A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol Endocrinol 14: 1550-1556.
44. Milam JE, Keshamouni VG, Phan SH, Hu B, Gangireddy SR, et al. (2008) PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294: L891-901.
45. Kulkarni A, Woeller CF, Thatcher TH, Ramon S, Phipps RP, et al. (2012) Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases. PPAR Research 2012: 1-13.
46. Catane R, Schwade JG, Turrisi AT 3rd, Webber BL, Muggia FM (1979) Pulmonary toxicity after radiation and bleomycin: a review. Int J Radiat Oncol Biol Phys 5: 1513-1518.
47. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J, (1997) Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 100: 768-776.